Form 4: Surgery Partners CFO Sells SGRY Shares

Surgery Partners CFO David T. Doherty sold 47,491 shares of common stock for $23.39 per share, a transaction executed under a pre-arranged 10b5-1 plan.

Summary

• David T. Doherty, Chief Financial Officer of Surgery Partners, Inc. (SGRY), sold 47,491 shares of the company's common stock.
• The sale occurred on August 8, 2025, at a weighted average price of $23.39 per share.
• Following this transaction, Mr. Doherty directly owns 103,377 shares of Surgery Partners common stock.
• The transaction was executed pursuant to a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 5

Explanation: Neutral. While an insider sale can be perceived negatively, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic selling based on non-public information. It's a routine liquidity event for an executive.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on new, non-public information.

Negatives

• An insider sale, even if pre-planned, reduces the insider's direct equity stake in the company.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context. However, insider transactions in healthcare services companies are routinely monitored for insights into management's confidence and liquidity needs.

Related Party Transactions

• The transaction involves the sale of common stock by David T. Doherty, the Chief Financial Officer of Surgery Partners, Inc., which is a related party transaction as defined by SEC regulations for insider reporting.

Stakeholder Impact

• Shareholders: The sale reduces the CFO's direct ownership, which could be interpreted as a slight decrease in alignment, though mitigated by the 10b5-1 plan. No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Key Dates

Recommendation

The filing details a routine insider stock sale executed under a Rule 10b5-1 plan. This type of transaction is typically pre-scheduled for liquidity or diversification purposes and does not usually signal a change in the company's fundamental outlook or performance. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Surgery Partners, SGRY, Insider Sale, Form 4, David T. Doherty, CFO, Stock Transaction, 10b5-1 Plan, Healthcare Services